Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study

Limited data are available about the cardiovascular (CV) safety and efficacy of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in ischemic stroke patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). Ischemic stroke patients with T2DM and CKD were selected from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Chung-Yu, Chen, Dong-Yi, Mao, Chun-Tai, Hsieh, I-Chang, Hung, Ming-Jui, Wang, Chao-Hung, Wen, Ming-Shien, Cherng, Wen-Jin, Chen, Tien-Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314701/
https://www.ncbi.nlm.nih.gov/pubmed/30593182
http://dx.doi.org/10.1097/MD.0000000000013844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314701/
https://www.ncbi.nlm.nih.gov/pubmed/30593182
http://dx.doi.org/10.1097/MD.0000000000013844

Ejemplares similares